Open Nav

Resverlogix Corp.

  • Kenneth Lebioda, Resverlogix Corp.

Update on the Phase 3 BETonMACE clinical trial

  • Date:Wednesday, October 17
  • Time:3:00 PM - 3:15 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low levels of high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have CKD.
  • Company
  • Company HQ City:Calgary
  • Company HQ Country:Canada
  • Company HQ State:Alberta
  • Ticker:RVX
  • Exchange:TSX
  • CEO/Top Company Official:Donald McCaffrey
  • Year Founded:2001
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development :Apabetalone
  • Development Phase of Primary Product:Phase III
  • Additional Information/Comments:Please CC Sarah Zapotichny on all communications
Kenneth Lebioda
Resverlogix Corp.